Targeting NAD+ in Metabolic Disease: New Insights Into an Old Molecule

Overview

Journal J Endocr Soc

Specialty Endocrinology

Date 2017 Dec 22

PMID 29264533

Citations 43

Authors

Yasir S Elhassan

Andrew A Philp

Gareth G Lavery

Affiliations

Soon will be listed here.

Abstract

Nicotinamide adenine dinucleotide (NAD+) is an established cofactor for enzymes serving cellular metabolic reactions. More recent research identified NAD+ as a signaling molecule and substrate for sirtuins and poly-adenosine 5'-diphosphate polymerases; enzymes that regulate protein deacetylation and DNA repair, and translate changes in energy status into metabolic adaptations. Deranged NAD+ homeostasis and concurrent alterations in mitochondrial function are intrinsic in metabolic disorders, such as type 2 diabetes, nonalcoholic fatty liver, and age-related diseases. Contemporary NAD+ precursors show promise as nutraceuticals to restore target tissue NAD+ and have demonstrated the ability to improve mitochondrial function and sirtuin-dependent signaling. This review discusses the accumulating evidence for targeting NAD+ metabolism in metabolic disease, maps the different strategies for NAD+ boosting, and addresses the challenges and open questions in the field. The health potential of targeting NAD+ homeostasis will inform clinical study design to identify nutraceutical approaches for combating metabolic disease and the unwanted effects of aging.

Citing Articles

Phenotypic diversity in NAXE mutations.

Solmaz I, Yalnizoglu D, Dursun A, Ciki K, Akar H, Koksal Ozgul R Neurol Sci. 2025; .

PMID: 39937421 DOI: 10.1007/s10072-025-08006-z.

Accelerated Sarcopenia Phenotype in the DJ-1/-Knockout Zebrafish.

Rostad K, Trognitz T, Froyset A, Bifulco E, Fladmark K Antioxidants (Basel). 2025; 13(12.

PMID: 39765837 PMC: 11673048. DOI: 10.3390/antiox13121509.

Nicotinic acid improves mitochondrial function and associated transcriptional pathways in older inactive males.

Deane C, Willis C, Gallagher I, Brook M, Gharahdaghi N, Wylie L Transl Exerc Biomed. 2024; 1(3-4):277-294.

PMID: 39703532 PMC: 11653476. DOI: 10.1515/teb-2024-0030.

Nicotinamide Riboside Ameliorates Fructose-Induced Lipid Metabolism Disorders in Mice by Activating Browning of WAT, and May Be Also Related to the Regulation of Gut Microbiota.

Zhang H, Zhao X, Zhang L, Sun D, Ma Y, Bai Y Nutrients. 2024; 16(22).

PMID: 39599706 PMC: 11597130. DOI: 10.3390/nu16223920.

Oxygen-Dependent Interactions between the Ruthenium Cage and the Photoreleased Inhibitor in NAMPT-Targeted Photoactivated Chemotherapy.

Abyar S, Huang L, Husiev Y, Bretin L, Chau B, Ramu V J Med Chem. 2024; 67(13):11086-11102.

PMID: 38924492 PMC: 11247496. DOI: 10.1021/acs.jmedchem.4c00589.

References

Worm D, Henriksen J, Vaag A, Melander A, Beck-Nielsen H . Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period. J Clin Endocrinol Metab. 1994; 78(3):717-21. DOI: 10.1210/jcem.78.3.8126147. View

Herranz D, Munoz-Martin M, Canamero M, Mulero F, Martinez-Pastor B, Fernandez-Capetillo O . Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat Commun. 2010; 1:3. PMC: 3641391. DOI: 10.1038/ncomms1001. View

Camacho-Pereira J, Tarrago M, Chini C, Nin V, Escande C, Warner G . CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metab. 2016; 23(6):1127-1139. PMC: 4911708. DOI: 10.1016/j.cmet.2016.05.006. View

Purushotham A, Schug T, Xu Q, Surapureddi S, Guo X, Li X . Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 2009; 9(4):327-38. PMC: 2668535. DOI: 10.1016/j.cmet.2009.02.006. View

Yin T, Britt J, De Jesus-Cortes H, Lu Y, Genova R, Khan M . P7C3 neuroprotective chemicals block axonal degeneration and preserve function after traumatic brain injury. Cell Rep. 2014; 8(6):1731-1740. PMC: 4206693. DOI: 10.1016/j.celrep.2014.08.030. View

Rouleau M, Patel A, Hendzel M, Kaufmann S, Poirier G . PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 2010; 10(4):293-301. PMC: 2910902. DOI: 10.1038/nrc2812. View

Kanfi Y, Naiman S, Amir G, Peshti V, Zinman G, Nahum L . The sirtuin SIRT6 regulates lifespan in male mice. Nature. 2012; 483(7388):218-21. DOI: 10.1038/nature10815. View

Escande C, Nin V, Price N, Capellini V, Gomes A, Barbosa M . Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. Diabetes. 2012; 62(4):1084-93. PMC: 3609577. DOI: 10.2337/db12-1139. View

Schmeisser K, Mansfeld J, Kuhlow D, Weimer S, Priebe S, Heiland I . Role of sirtuins in lifespan regulation is linked to methylation of nicotinamide. Nat Chem Biol. 2013; 9(11):693-700. PMC: 4076143. DOI: 10.1038/nchembio.1352. View

10.

Leamy A, Egnatchik R, Shiota M, Ivanova P, Myers D, Brown H . Enhanced synthesis of saturated phospholipids is associated with ER stress and lipotoxicity in palmitate treated hepatic cells. J Lipid Res. 2014; 55(7):1478-88. PMC: 4076085. DOI: 10.1194/jlr.M050237. View

11.

Opitz C, Heiland I . Dynamics of NAD-metabolism: everything but constant. Biochem Soc Trans. 2015; 43(6):1127-32. DOI: 10.1042/BST20150133. View

12.

Nirsimloo R, Gourley C . The safety and efficacy of olaparib therapy in patients with relapsed ovarian cancer. Expert Rev Anticancer Ther. 2016; 16(6):597-603. DOI: 10.1080/14737140.2016.1182429. View

13.

Chalkiadaki A, Guarente L . High-fat diet triggers inflammation-induced cleavage of SIRT1 in adipose tissue to promote metabolic dysfunction. Cell Metab. 2012; 16(2):180-8. PMC: 3539750. DOI: 10.1016/j.cmet.2012.07.003. View

14.

Zhou C, Yang X, Hua X, Liu J, Fan M, Li G . Hepatic NAD(+) deficiency as a therapeutic target for non-alcoholic fatty liver disease in ageing. Br J Pharmacol. 2016; 173(15):2352-68. PMC: 4945761. DOI: 10.1111/bph.13513. View

15.

Hirschey M, Shimazu T, Goetzman E, Jing E, Schwer B, Lombard D . SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature. 2010; 464(7285):121-5. PMC: 2841477. DOI: 10.1038/nature08778. View

16.

Collins P, Chaykin S . The management of nicotinamide and nicotinic acid in the mouse. J Biol Chem. 1972; 247(3):778-83. View

17.

Frederick D, Loro E, Liu L, Davila Jr A, Chellappa K, Silverman I . Loss of NAD Homeostasis Leads to Progressive and Reversible Degeneration of Skeletal Muscle. Cell Metab. 2016; 24(2):269-82. PMC: 4985182. DOI: 10.1016/j.cmet.2016.07.005. View

18.

Gibson B, Kraus W . New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat Rev Mol Cell Biol. 2012; 13(7):411-24. DOI: 10.1038/nrm3376. View

19.

Pirinen E, Canto C, Jo Y, Morato L, Zhang H, Menzies K . Pharmacological Inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle. Cell Metab. 2014; 19(6):1034-41. PMC: 4047186. DOI: 10.1016/j.cmet.2014.04.002. View

20.

Lin J, Handschin C, Spiegelman B . Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab. 2005; 1(6):361-70. DOI: 10.1016/j.cmet.2005.05.004. View